Head-to-head evidence
Anhui HygeianCells EE001 vs CardiAMP
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Cardiac cell therapy · full Heart Failure pipeline
Anhui HygeianCells EE001
Developed by Anhui HygeianCells BioMedical
NCT06884111 · Phase 1 · completed
Only 6 people received the drug, all in a single open, unblinded group with no placebo or comparison arm, so any change seen cannot be attributed to the drug with confidence. No results have been posted yet.
CardiAMP
Developed by BioCardia
NCT02438306 · Phase 3 · completed
The study randomized 125 participants to CardiAMP or a sham procedure and masked participants and outcome assessors. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: April 2027 · NCT06258447 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anhui HygeianCells EE001's landscape · CardiAMP's landscape